Azenta (LTS:0HQ1) Debt-to-Asset : 0.03 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Azenta Debt-to-Asset?

Azenta's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.0 Mil. Azenta's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $54.3 Mil. Azenta's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $2,041.2 Mil. Azenta's debt to asset for the quarter that ended in Dec. 2024 was 0.03.

Azenta Debt-to-Asset Historical Data

The historical data trend for Azenta's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Debt-to-Asset Chart

Azenta Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.05

0.01

0.02

0.03

Azenta Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.02	0.03	0.03	0.03	0.03

Competitive Comparison of Azenta's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Azenta's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azenta's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Azenta's Debt-to-Asset falls into.

Azenta Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Azenta's Debt-to-Asset for the fiscal year that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	58.792)	/	2100.041
	=	0.03

Azenta's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	54.341)	/	2041.21
	=	0.03

Azenta (LTS:0HQ1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Azenta Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Azenta's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Azenta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (LTS:0HQ1) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AZTA:USA BA3:Germany

Address

200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803

Website

https://www.azenta.com

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.

Azenta Headlines

No Headlines